3rd Annual Spinal Muscular Atrophy Continuing Medical Education Conference on Clinical Decision-Making in the Midst of an Unfolding Phenotype

2 – 4 December 2021

Stanford continuing medical education and training contribute for the enhancement of knowledge and understanding of healthcare providers including physicians, specialists, physical, occupational, and speech language pathologist and nurses, outside specialized centers, in the clinical decision-making and medical and rehabilitative management of individuals with SMA.

For that purpose, it has organize a virtual 3-day brunch seminar series is provided to (1) integrate new 2021 treatment advances into clinical decision-making; and (2) use new SMA standards as a model for public health, primary and multi-disciplinary care of all children and adults with neuromuscular disease.

The aim is to build momentum among the healthcare community treating and managing individuals with SMA. In this era of disease-modifying treatments, evolving SMA phenotypes are unfolding and clinical decision-making is requiring greater attention for the most optimal outcomes. Multidisciplinary medical and rehabilitative management recommendations are sought after while weighing the treatment options, long term outcomes, and ethical considerations to effectively treat and manage patients with SMA.


The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission

“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern